Catumaxomab
- Generic Name
- Catumaxomab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 509077-98-9
- Unique Ingredient Identifier
- M2HPV837HO
- Background
Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites . Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. Catumaxumab was approved for market in Canada in May 2012 for the same condition . It is currently available under the brand name Removab.
- Indication
For use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible .
- Associated Conditions
- Ascites, Malignant
- Associated Therapies
- Palliative Treatment
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Neovii Biotech
- Target Recruit Count
- 47
- Registration Number
- NCT00377429
- Locations
- 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States
🇺🇸Stanford University of Obstetrics and Gynecology, Stanford, California, United States
🇺🇸Gynecologic Oncology - Hinsdale, Hinsdale, Illinois, United States
Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma
- Conditions
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2007-10-26
- Lead Sponsor
- Neovii Biotech
- Target Recruit Count
- 40
- Registration Number
- NCT00352833
- Locations
- 🇩🇪
Hospital of Cologne-Merheim, Surgical Department, Cologne, Germany
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Neovii Biotech
- Target Recruit Count
- 32
- Registration Number
- NCT00326885
- Locations
- 🇺🇸
Magee Women's Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
🇺🇸University of Louisville Cancer Center, Louisville, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.